Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatocyte-independent PAR1-biased signaling controls liver pathology in experimental obesity.

Journal of thrombosis and haemostasis : JTH - 1 Nov 2024

Cline Holly, Wei Zimu, Groeneveld Dafna J, Hix Jeremy M L, Xu Xiao, Flick Matthew J, Palumbo Joseph S, Poole Lauren G, Dockendorff Chris, Griffin John H, Luyendyk James P

Abstract excerpt

BACKGROUND: Protease-activated receptor-1 (PAR1) has emerged as an important link between coagulation and the complications of obesity including metabolic dysfunction-associated steatotic liver disease (MASLD). PAR1 is expressed by various cells and cleaved by different proteases to generate unique tethered agonists that activate distinct signaling pathways. Mice expressing PAR1 with an R41Q mutation have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diet, High-Fat
Share to Fatty Liver

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatocytes

Share to Insulin Resistance

Share to Non-alcoholic Fatty Liver Disease

Share to Obesity

Share to Receptor, PAR-1

Source

Open in PubMed Open full text

Identifiers

PMID: 39122189
DOI: 10.1016/j.jtha.2024.07.017
PMCID: PMC11513232

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatocyte-independent PAR1-biased signaling controls liver pathology in experimental obesity.PMID 39122189Read ↗

Protease-Activated Receptor 2 and Its Role in the Progression from Metabolic-Disfunction Associated Steatotic Liver Disease to Hepatocellular CarcinomaSemantic proximity Read ↗

Rap1 Activation Protects Against Fatty Liver and Non-Alcoholic Steatohepatitis DevelopmentSemantic proximity Read ↗

Loss of Par-1a/MARK3/C-TAK1 kinase leads to reduced adiposity, resistance to hepatic steatosis, and defective gluconeogenesis.Semantic proximity Read ↗

Macrophage Plg-RKT expression promotes diet-induced obesity and metabolic dysfunction-associated steatotic liver disease.Semantic proximity Read ↗

Hepatocyte Rap1a Contributes To Obesity- and Statin-Associated HyperglycemiaSemantic proximity Read ↗

Loss of Serpina1 in Mice Leads to Altered Gene Expression in Inflammatory and Metabolic PathwaysSemantic proximity Read ↗

Caspase-1 regulates TBK1 and PPARα to suppress steatosis-associated hepatocarcinogenesisSemantic proximity Read ↗

CXCR3+ LEF1low NK cells cause immunopathological hepatic damage in MASHSemantic proximity Read ↗

Low-Density Lipoprotein Receptor-Related Protein-1 Protects Against Hepatic Insulin Resistance and Hepatic Steatosis.Semantic proximity Read ↗

Pin1 Plays Essential Roles in NASH Development by Modulating Multiple Target Proteins.Semantic proximity Read ↗

Targeting Circulating FABP4 Ameliorates Obesity-Associated Hepatic SteatosisSemantic proximity Read ↗

Hepatic stellate cells-specific Loxl1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH miceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.